Outcome of Board Meeting

LINCOLN PHARMACEUTICALS LTD. HEALTHCARE FOR ALL Date: August 13, 2026 To, To, The Manager, Listing Department, The Department of Corporate Service, National Stock Exchange of India BSE Limited, Limited (NSE), 1st Floor, New Trading Ring, Rotunda Building, Exchange Plaza, C - 1, Block - G, Sandra - Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai - Kurla Complex, Sandra (E), Mumbai-400 400 001. 051. Svmbol - LINCOLN ScriD Code - 531633 Dear Sir, SUB.; OUTCOME OF BOARD MEETING. Further to our intimation dated August 06, 2026, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations"), we would like to inform that the Board of Directors of the Company at its meeting held today i.e. on Thursday, August 13, 2026, have considered/approved/recommended, inter alia, the followings: - 1. The un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2026 along with the limited review report from auditors thereon. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of un-audited consolidated financial results for the quarter ended on June 30, 2026. The un-audited financial results (standalone and consolidated) will be available at Company's website at www.lincolnpharma.com. Further, we enclose herewith financial highlights for the aforesaid quarter. MeetingoftheBoardofDirectorscommencedat ·\O ·.30 and concluded at \I :30 A.M. Kindly take the same on your records. Thanking you, Yours faithfully, Trusha Shah Company Secretary & Compliance Officer Encl: A/a Regd, Office : "Lincoln House", B/h. Satyam Complex, Science City Road. Sola. Ahmedabad-380060, Gujarat, India Phone: +91-79-4107 8000 I CIN L24230GJ1995PLC024288 E-mail: mfo§lmcolnpharrna.corn I Website: www.tmcolnpharma.com Factory: Tnmul Estate, Khatraj, Tal.- Kaloi, Dist.- Gandhinagar-382721, Gujarat State, India Phone: +91-79-4913 5000 l E-mail: khatra1gjlincolnpharma.com LINCOLN PHARMACEUTICALS LIMITED Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060. CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000, Website: www.lincolnpharma.com E-Mail: investor@lincolnpharma.com Statement of Standalone Un-Audited Financial Results for the Quarter Ended on 30-June-2026. in Lakhs) Quarter Ended Year Ended 30/06/2026 31/03/2026 30/06/2025 31/03/2026 Sr. No. Particulars (Un-Audited) Refer No. 3 (Un-Audited) (Audited) 1 Income A) Revenue From Operations 17,728.21 18,727.73 15,406.67 67,102.99 B) Other Income 2 426.46 (419.53) 1 527.17 3 345.40 Total Income (1) 20,154.67 18,308.20 16,933.84 70,448.39 2 Expenses A) Cost of Material Consumed 5,857.86 7,372.58 6,096.93 23,957.41 B) Purchase of Stock-In-Trade 2,093.36 1,644.69 1,583.06 7,902.55 C) Changes In Inventories of Finished Goods, Stock- 563.09 (110.23) (741.56) (743.96) In-Trade and WIP D) Employee Benefits Expenses 3,331.03 3,245.79 3,175.68 12,518.86 E) Finance Costs 25.87 27.43 20.98 101.29 F) Deprecation and Amortisation Expense 388.43 368.28 347.72 1,449.96 G) Other Expenses 3 139.65 4.089.40 2 912.11 13 699.78 Total Expenses (2) 15,399.29 16,637.94 13.394.92 58,885.89 Profit/ (Loss) Before Exceptional Items & Tax 3 4,755,38 1,670.26 3,538.92 11,562.50 (1-2) 4 Exceptional Items Nil Nil Nil Nil Profit / (Loss) after Exceptional items but 5 4,755.38 1,670.26 3,538.92 11,562.50 Before Tax (3-4) Tax Expense 6 A) Current Tax 535.30 861.90 412.30 2,737.10 B) Deferred Tax 596.63 (360.98) 359.10 (3.09) C) Short I (Excess) Tax Provision Nil 5.88 Nil 39.11 7 Net Profit I (Loss) For The Period (5-6) 3,623.45 1.163.46 2.767.52 8,789.38 Other Comprehensive Income (Net Of Tax) Items that will not be reclassified to subsequently 41.88 160.63 2.29 167.50 8 to profit and loss Items that will be reclassified subsequently to Nil Nil Nil Nil profit or loss 9 Total Comprehensive Income 3,665.33 1324.09 2,769.81 8,956.88 Paid-Up Equity Share Capital (Face Value Of Rs. 10/- 10 2,002.97 2,002.97 2,002.97 2,002.97 Each) 11 Other Equity 73,760.23 Earnings Per Share (of Rs. 10/- Each) (Not Annualised) (a) Basic 18.09 5.81 13.82 43.88 (b) Diluted 18.09 5.81 13.82 43.88 NOTES: The above unaudited standalone financial results of the Company for the quarter ended June 30, 2026 have been 1 reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, August 13, 2026. The auditor have carried out an limited review of the said financial results. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind 2 AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent aoolicable. The figures for the quarter ended March 31, 2026 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year. 4 The Company has a slnqle business seqment namely 'Pharmaceutical Business'. The figures for the previous period / year have been regrouped I reclassified, wherever necessary to conform to current period I year classification. - For Lincoln Pharmaceuticals Limited I Cl . � � � Z C)>l 1 -' r- 1.·cv� Mahendra G. Patel Place: Ahmedabad - Managing Director Date: Auaust 13, 2026 DIN:00104706 SAMIR M. SHAH & ASSOCIATES Chartered Accountants "Heaven", 8, Western Park Society, Nr. TRP Mall, Bopal, Ahmedabad - 380058 Phone: +91- 76220 12032 E-mail : samir@smshah.co.in Limited Review Report on standalone un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. To the Board of Directors of, Lincoln Pharmaceuticals Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results of Lincoln Pharmaceuticals Limited ("the Company") having its Registered Office at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad - 380060, Gujarat for the quarter ended June 30, 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. The Statement includes the results for the quarter ended 31st March 2026 being the derived figures between the audited figures in respect of the full financial year ended 31st March 2026 and the unaudited year-to-date figures upto 3l51December 2025 which were subjected to a limited review. 2. Management's Responsibility for the statement: This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"}, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. 3. Auditor's Responsibility: We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the s Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of lndia .. , as: .. This standard requires that we plan and perform the review to obtain moderate assurance to whether the financial statements are free of material misstatement. A review is limited" primarily to inquiries of company personnel and analytical procedures applied to financial data· and thus provide less assurance than an audit. We have not performed an audit and,� accordingly, we do [Showing first 8,000 characters — download PDF for full document]